SEC Form 144 filed by Rockwell Medical Inc.

$RMTI
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RMTI alert in real time by email

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Get the next $RMTI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RMTI

DatePrice TargetRatingAnalyst
11/14/2024$5.00Buy
Rodman & Renshaw
1/18/2022$5.00 → $3.00Buy
HC Wainwright & Co.
9/7/2021$5.50 → $5.00Buy
HC Wainwright & Co.
More analyst ratings

$RMTI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

    Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rockwell Medical to Exhibit at DialysisTechConneXion42 in Booth# 112

    Conference will take place April 1-4, 2025 in Las Vegas, Nevada Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion42 ("DTX42"). Hosted by the National Association of Nephrology Technicians/Technologists, DTX42 will be held at Planet Hollywood in Las Vegas, Nevada from April 1-4, 2025. Rockwell Medical is exhibiting in Booth #112. Visitors to Rockwell Medical's booth can get a first-hand look at the Company's hemodialysis conce

    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rockwell Medical Named 'Great Place to Work' for Third Year in a Row

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has been certified as a Great Place to Work® for the third year in a row. "We have built a high-trust culture here are Rockwell Medical with team members who are invested in the success of our organization," said Lesley Spriggs, Vice President of Human Resources at Rockwell Medical. "Being named a 'Great Place to Work' for the third year in a row reflects the tremendous progress that we have made over the past several years fostering a workplace that sup

    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RMTI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RMTI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RMTI
SEC Filings

See more

$RMTI
Leadership Updates

Live Leadership Updates

See more
  • Universal Display Corporation Announces the Appointment of New Board Members

    Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

    $BDN
    $NOTV
    $OLED
    $RMTI
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

    Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

    $BDN
    $RMTI
    $RCOR
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

    WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci

    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RMTI
Financials

Live finance-specific insights

See more
  • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

    Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rockwell Medical to Release Fourth Quarter and Full-Year 2024 Results on Thursday, March 20, 2025

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2024 on Thursday, March 20, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, March 20, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMe

    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rockwell Medical Reports Third Quarter 2024 Earnings, Generates Profitability on a Cash Flow and Adjusted EBITDA Basis for the Second Consecutive Quarter

    Reports net product sales of $28.3 million for the third quarter of 2024, an increase of 31% over net product sales for the same period in 2023. Net product sales for the third quarter of 2024 included a special large order of premium-priced products by our largest customer. Reports gross profit of $6.2 million for the third quarter of 2024, an increase of 183% over the same period in 2023. Achieves gross margin of 22% for the third quarter of 2024 compared to a gross margin of 9% for the same period in 2023. Generates $4.3 million in cash flow from operations for the third quarter of 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops

    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RMTI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more